The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism
暂无分享,去创建一个
G. Lip | W. Ageno | P. Prandoni | A. Tosetto | S. Testa | D. Poli | E. Antonucci | G. Palareti | D. Mastroiacovo | V. Pengo | A. Goodin
[1] W. Ageno,et al. The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism: reply , 2018, Journal of thrombosis and haemostasis : JTH.
[2] Joshua D. Brown,et al. Risk Stratification for Bleeding Complications in Patients With Venous Thromboembolism: Application of the HAS‐BLED Bleeding Score During the First 6 Months of Anticoagulant Treatment , 2018, Journal of the American Heart Association.
[3] T. Chao,et al. Incident Risk Factors and Major Bleeding in Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk Factors , 2018, Thrombosis and Haemostasis.
[4] J. Rivera‐Caravaca,et al. Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial , 2017, Thrombosis and Haemostasis.
[5] G. Guyatt,et al. Discrimination and Calibration of Clinical Prediction Models: Users’ Guides to the Medical Literature , 2017, JAMA.
[6] P. Wells,et al. Bleeding risk in patients with unprovoked venous thromboembolism: A critical appraisal of clinical prediction scores. , 2017, Thrombosis research.
[7] M. Fang,et al. Scoring Systems for Estimating the Risk of Anticoagulant-Associated Bleeding , 2017, Seminars in Thrombosis and Hemostasis.
[8] F. Klok,et al. External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism , 2017, Thrombosis and Haemostasis.
[9] P. Reitsma,et al. Brave real world , 2016, Journal of thrombosis and haemostasis : JTH.
[10] D. Lane,et al. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores , 2016, Journal of thrombosis and haemostasis : JTH.
[11] S. Schulman,et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment , 2016, European Respiratory Journal.
[12] W. Ageno,et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH , 2016, Journal of thrombosis and haemostasis : JTH.
[13] S. Yusuf,et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study , 2016, The Lancet.
[14] G. Lip,et al. The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE , 2016, Thrombosis and Haemostasis.
[15] S. Schulman,et al. Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.
[16] N. Magrini,et al. The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation , 2015, PloS one.
[17] P. Prandoni,et al. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. , 2014, Blood.
[18] F. Pomero,et al. Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism , 2014, Thrombosis and Haemostasis.
[19] P. Prandoni,et al. Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism: findings from the RIETE registry , 2014, Internal and Emergency Medicine.
[20] G. Raskob,et al. Apixaban for extended treatment of venous thromboembolism. , 2013, The New England journal of medicine.
[21] S. Goldhaber,et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. , 2013, The New England journal of medicine.
[22] E. Akl,et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.
[23] R. Gans,et al. Oral rivaroxaban for symptomatic venous thromboembolism. , 2011, The New England journal of medicine.
[24] Gregory Y H Lip,et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. , 2011, Journal of the American College of Cardiology.
[25] Bruce L Davidson,et al. Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.
[26] Gregory Y H Lip,et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.
[27] M. Monreal,et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry , 2008, Thrombosis and Haemostasis.
[28] S. Pocock,et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, BMJ : British Medical Journal.
[29] Matthias Egger,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies , 2007, PLoS medicine.
[30] S. Schulman,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.
[31] Keith C. Norris,et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[32] M. Prins,et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. , 1999, Archives of internal medicine.
[33] R. Beyth,et al. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. , 1998, The American journal of medicine.
[34] Paolo Prandoni,et al. The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.
[35] F R Rosendaal,et al. A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.
[36] L Goldman,et al. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. , 1989, The American journal of medicine.
[37] F. García-Bragado Dalmau. [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism]. , 2013, Revista clinica espanola.
[38] Cockcroft Dw,et al. Prediction of Creatinine Clearance from Serum Creatinine , 1976 .